Molecular Genetic, Cellular Electrophysiological Study Of Brugada Syndrome

Backgroud:Since its introduction as a clinical entity in 1992, the Brugada syndrome has attracted great interest. During the first and second virtual symposium on the Brugada syndrome, held in 2002 and 2003, the proposal was made to use the term "disease" since it has characteristic signs, symptoms, and an identified genetic defect. The Brugada syndrome is associated with a high risk for sudden cardiac death caused by polymorphic ventricular tachycardia or fibrillation (VT/VF) in young and otherwise healthy adults, less frequently in infants and children, and electrocardiographically characterized by a typical electrocardiographic(ECG) pattern that consists of varying degrees of right bundle branch block (RBBB) and ST-segment elevation in the V1-V3 leads, coved or saddleback-shaped, and the ECG manifestations of Brugada syndrome are often dynamic or concealed and may be elicited by class I_C drugs (ajmaline, flecainide, propafenone), antidepressant drugs,...